# Lucent AD Complete

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/lucent-ad-complete
Canonical HTML page: https://getbiobrief.com/entity/lucent-ad-complete

## Timeline

- **2026-03-02**: Q4 2025 Earnings — Company reports 25% total revenue growth and progress in clinical diagnostic pivot.
- **2026-01-15**: FDA 510(k) Submission — Premarket notification submitted for Lucent AD Complete diagnostic test.
- **2025-12-31**: CMS Reimbursement Milestone — CMS approves $897 reimbursement rate for Lucent AD Complete, establishing a national reference price.
- **2025-01-01**: Assay Portfolio Expansion — Launch of 13 new assays including pTau-205 and pTau-212 for neurodegenerative research.

## Recent coverage (1 stories)

### Quanterix Advances Alzheimer’s Strategy Amidst 25% Revenue Growth and FDA Filing
2026-03-04 00:21:33 · Sentiment: Positive · Impact: 6/10 · Sources: 6

Quanterix reported Q4 2025 revenue of $43.9 million, driven by a 25% year-over-year increase and significant progress in its Alzheimer’s diagnostic portfolio. Despite organic declines in its core Simoa and Spatial segments, the company secured a $897 CMS reimbursement rate for its Lucent AD Complete test and submitted its 510(k) to the FDA.
Full story: https://getbiobrief.com/story/quanterix-q4-2025-alzheimers-diagnostic-strategy-fda-filing

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.